TRCT
NEXI

Tower Research Capital (TRC)’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Tower Research Capital (TRC)’s Portfolio NEXI Stock Details NEXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,121
Closed -$5.85K – 6135
2024
Q2 		$5.85K Buy
2,121
+541
+34% +$1.82K ﹤0.01% 4644
2024
Q1 		$8.86K Sell
1,580
-221
-12% -$1.7K ﹤0.01% 3944
2023
Q4 		$4K Buy
1,801
+1,545
+604% +$5.21K ﹤0.01% 5010
2023
Q3 		$1.34K Hold
256
– – ﹤0.01% 5358
2023
Q2 		$1.8K Sell
256
-5
-2% -$43 ﹤0.01% 5316
2023
Q1 		$2K Hold
261
– – ﹤0.01% 5432
2022
Q4 		$2K Sell
261
-296
-53% -$3.69K ﹤0.01% 5463
2022
Q3 		$8K Buy
557
+383
+220% +$11.2K ﹤0.01% 4835
2022
Q2 		$7K Sell
174
-71
-29% -$4.4K ﹤0.01% 4847
2022
Q1 		$26K Buy
245
+132
+117% +$9.69K ﹤0.01% 3302
2021
Q4 		$13K Buy
113
+92
+438% +$22.1K ﹤0.01% 4221
2021
Q3 		$8K Sell
21
-34
-62% -$11.4K ﹤0.01% 4583
2021
Q2 		$22K Buy
55
+45
+450% +$20.7K ﹤0.01% 3820
2021
Q1 		$5K Buy
+10
New +$5.44K ﹤0.01% 4717

Other funds holding NEXI

RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Tower Research Capital (TRC)'s NEXI Position: Q3 2024 in Review

Tower Research Capital (TRC) sold out of NexImmune, Inc. Common Stock (NEXI) in Q3 2024, closing a stake of 2,121 shares — an estimated $5.85K sold.

Tower Research Capital (TRC) first reported a position in NEXI in Q1 2021 and held it in 14 quarters. The position peaked at $26K in Q1 2022. 1 fund tracked by Wall St. Rank holds NEXI as of Q3 2024.

  • Tower Research Capital (TRC) reported no remaining NexImmune, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,121 NexImmune, Inc. Common Stock shares in Q3 2024, an estimated $5.85K.
  • Tower Research Capital (TRC) first reported a position in NexImmune, Inc. Common Stock in Q1 2021 and held it in 14 quarters.
  • Tower Research Capital (TRC)'s NexImmune, Inc. Common Stock position peaked at $26K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q3 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2024, filed 14 Nov 2024.